Literature DB >> 31401339

Corrigendum to "TFOS DEWS II pathophysiology report" [Ocul. Surf. 15 (3) (2017) 438-510].

Anthony J Bron1, Cintia S de Paiva2, Sunil K Chauhan3, Stefano Bonini4, Eric E Gabison5, Sandeep Jain6, Erich Knop7, Maria Markoulli8, Yoko Ogawa9, Victor Perez10, Yuichi Uchino9, Norihiko Yokoi11, Driss Zoukhri12, David A Sullivan3.   

Abstract

Entities:  

Year:  2019        PMID： 31401339     DOI： 10.1016/j.jtos.2019.08.007

Source DB:  PubMed          Journal:  Ocul Surf        ISSN： 1542-0124            Impact factor:   5.033


× No keyword cloud information.
  3 in total

1.  A combination of CMC and α-MSH inhibited ROS activated NLRP3 inflammasome in hyperosmolarity stressed HCECs and scopolamine-induced dry eye rats.

Authors:  Ying Lv; Chenchen Chu; Ke Liu; Yusha Ru; Yan Zhang; Xiaoxiao Lu; Yichen Gao; Caijie Zhang; Shaozhen Zhao
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

2.  The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling.

Authors:  Fang-Ming Yang; Di Fan; Xiao-Qian Yang; Feng-Hua Zhu; Mei-Juan Shao; Qian Li; Yu-Ting Liu; Ze-Min Lin; Shi-Qi Cao; Wei Tang; Shi-Jun He; Jian-Ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2020-08-03       Impact factor: 6.150

3.  Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease.

Authors:  Sangeeta Kumari; Madhuri Dandamudi; Sweta Rani; Elke Behaeghel; Gautam Behl; David Kent; Niall J O'Reilly; Orla O'Donovan; Peter McLoughlin; Laurence Fitzhenry
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.